Pfizer Gives FDA its Data on Vaccine for Children Ages 5-11
A clinical trial in that age group had shown favorable results
On Tuesday, Pfizer and BioNTech announced they had submitted data to the Food and Drug Administration (FDA) that the companies said showed that their coronavirus vaccine is safe and effective in children ages 5 to 11.
The companies said that they would submit a formal request to regulators to allow a pediatric dose of their vaccine to be administered in the United States in the coming weeks. Similar requests will be filed with European regulators and in other countries.
The announcement, coming as U.S. schools have resumed amid a ferocious Delta wave, brings many parents another step closer to the likelihood of a COVID-19 vaccine for their children.
Please select this link to read the complete article from The New York Times.